CIK 0001070081 · Large accelerated filer
PTC THERAPEUTICS, INC.
Sign in to watch- Ticker
- PTCT
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043416587
- Phone
- 9082227000
- Business address
- 500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ, 07059
- Former names
- PTC THERAPEUTICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $7,752,145
- in 10 filings, $7.8M under 10b5-1 plans
Net −$7,752,145. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-10-03 | Reeve Emma Director | Sale 10b5-1 | −2,729 | $65.05 | $178K | 16,253 |
| 2025-10-03 | Reeve Emma Director | Sale 10b5-1 | −4,037 | $66.10 | $267K | 12,216 |
| 2025-10-03 | Reeve Emma Director | Sale 10b5-1 | −1,884 | $66.89 | $126K | 10,332 |
| 2025-10-03 | Reeve Emma Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 0 | ||
| 2025-10-03 | Reeve Emma Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −6,912 | 0 | ||
| 2025-10-03 | Reeve Emma Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −8,650 | 0 | ||
| 2025-10-03 | Jacobson Allan Steven Director | Option exercise 10b5-1 | +12,000 | $30.86 | $370K | 29,451 |
| 2025-10-03 | Jacobson Allan Steven Director | Sale 10b5-1 | −12,000 | $65.00 | $780K | 17,451 |
| 2025-10-03 | Jacobson Allan Steven Director | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,000 | 0 | ||
| 2025-10-03 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +18,124 | $39.42 | $714K | 122,025 |
| 2025-10-03 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −3,100 | $64.43 | $200K | 118,925 |
| 2025-10-03 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −6,124 | $65.47 | $401K | 112,801 |
| 2025-10-03 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −7,400 | $66.44 | $492K | 105,401 |
| 2025-10-03 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −1,500 | $67.15 | $101K | 103,901 |
| 2025-10-03 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +2,266 | $39.42 | $89K | 106,167 |
| 2025-10-03 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −536 | $64.43 | $35K | 105,631 |
| 2025-10-03 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −824 | $65.73 | $54K | 104,807 |
| 2025-10-03 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −906 | $66.63 | $60K | 103,901 |
| 2025-10-03 | Boulding Mark Elliott EXEC. VP AND CLO | Option exercise 10b5-1 | +2,265 | $39.42 | $89K | 106,166 |
| 2025-10-03 | Boulding Mark Elliott EXEC. VP AND CLO | Sale 10b5-1 | −550 | $64.44 | $35K | 105,616 |
Page 21 of 25 · 493 trades